Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry.
Poly-vascular disease
clinical trial
human
percutaneous coronary intervention
vascular disease
Journal
European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796
Informations de publication
Date de publication:
21 06 2023
21 06 2023
Historique:
received:
21
02
2022
revised:
02
06
2022
accepted:
21
07
2022
medline:
23
6
2023
pubmed:
26
7
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
Multisite artery disease is considered a 'malignant' type of atherosclerotic disease associated with an increased cardiovascular risk, but the impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention (PCI) is unknown. Patients enrolled in the large, prospective e-Ultimaster study were grouped into (1) those without known prior vascular disease, (2) those with known single-territory vascular disease, and (3) those with known two to three territories (i.e coronary, cerebrovascular, or peripheral) vascular disease (multisite artery disease). The primary outcome was coronary target lesion failure (TLF), defined as the composite of cardiac death, target vessel-related myocardial infarction, and clinically driven target lesion revascularization at 1-year. Inverse propensity score weighted (IPSW) analysis was performed to address differences in baseline patient and lesion characteristics. Of the 37 198 patients included in the study, 62.3% had no prior known vascular disease, 32.6% had single-territory vascular disease, and 5.1% had multisite artery disease. Patients with known vascular disease were older and were more likely to be men and to have more co-morbidities. After IPSW, the TLF rate incrementally increased with the number of diseased vascular beds (3.16%, 4.44%, and 6.42% for no, single, and multisite artery disease, respectively, P < 0.01 for all comparisons). This was also true for all-cause death (2.22%, 3.28%, and 5.29%, P < 0.01 for all comparisons) and cardiac mortality (1.26%, 1.91%, and 3.62%, P ≤ 0.01 for all comparisons). Patients with previously known vascular disease experienced an increased risk of adverse cardiovascular events and mortality post-PCI. This risk is highest among patients with multisite artery disease. Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02188355.
Sections du résumé
BACKGROUND
Multisite artery disease is considered a 'malignant' type of atherosclerotic disease associated with an increased cardiovascular risk, but the impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention (PCI) is unknown.
METHODS
Patients enrolled in the large, prospective e-Ultimaster study were grouped into (1) those without known prior vascular disease, (2) those with known single-territory vascular disease, and (3) those with known two to three territories (i.e coronary, cerebrovascular, or peripheral) vascular disease (multisite artery disease). The primary outcome was coronary target lesion failure (TLF), defined as the composite of cardiac death, target vessel-related myocardial infarction, and clinically driven target lesion revascularization at 1-year. Inverse propensity score weighted (IPSW) analysis was performed to address differences in baseline patient and lesion characteristics.
RESULTS
Of the 37 198 patients included in the study, 62.3% had no prior known vascular disease, 32.6% had single-territory vascular disease, and 5.1% had multisite artery disease. Patients with known vascular disease were older and were more likely to be men and to have more co-morbidities. After IPSW, the TLF rate incrementally increased with the number of diseased vascular beds (3.16%, 4.44%, and 6.42% for no, single, and multisite artery disease, respectively, P < 0.01 for all comparisons). This was also true for all-cause death (2.22%, 3.28%, and 5.29%, P < 0.01 for all comparisons) and cardiac mortality (1.26%, 1.91%, and 3.62%, P ≤ 0.01 for all comparisons).
CONCLUSIONS
Patients with previously known vascular disease experienced an increased risk of adverse cardiovascular events and mortality post-PCI. This risk is highest among patients with multisite artery disease.
Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02188355.
Identifiants
pubmed: 35876646
pii: 6649650
doi: 10.1093/ehjqcco/qcac043
pmc: PMC10284265
doi:
Banques de données
ClinicalTrials.gov
['NCT02188355']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
417-426Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Int J Mol Sci. 2016 Sep 06;17(9):
pubmed: 27608017
Eur Heart J. 2018 Mar 1;39(9):763-816
pubmed: 28886620
Circ J. 2013;77(1):89-95
pubmed: 23018634
Int J Cardiol. 2018 Jun 15;261:6-11
pubmed: 29657058
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):541-9
pubmed: 22715460
Circulation. 2018 Jan 23;137(4):338-350
pubmed: 29133605
JAMA Netw Open. 2018 Nov 2;1(7):e185239
pubmed: 30646395
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
Am J Cardiol. 2003 Oct 15;92(8):964-6
pubmed: 14556873
Eur Heart J. 2009 May;30(10):1195-202
pubmed: 19339264
Ann Cardiol Angeiol (Paris). 2020 Oct;69(4):158-166
pubmed: 32778388
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
Circ Cardiovasc Interv. 2019 Dec;12(12):e007385
pubmed: 31833412
Int J Cardiol. 2021 Sep 15;339:70-74
pubmed: 34246725
N Engl J Med. 2017 Oct 5;377(14):1319-1330
pubmed: 28844192
Rambam Maimonides Med J. 2020 Apr 29;11(2):
pubmed: 32374258
Circulation. 2019 Jul 16;140(3):240-261
pubmed: 31116032
Circ Res. 2021 Jun 11;128(12):1818-1832
pubmed: 34110907
Front Biosci (Schol Ed). 2021 Dec 3;13(2):173-180
pubmed: 34879469
J Am Heart Assoc. 2017 Oct 24;6(10):
pubmed: 29066452
Eur J Clin Invest. 2014;44(3):231-9
pubmed: 24372467
Int J Cardiol. 2021 Mar 15;327:1-8
pubmed: 33271206
Heart. 2022 Jul 27;108(16):1310-1318
pubmed: 35012960
Atherosclerosis. 2022 Mar;344:71-77
pubmed: 35135696
J Am Heart Assoc. 2020 Dec 15;9(24):e017740
pubmed: 33287626
J Cardiovasc Dev Dis. 2021 Jan 27;8(2):
pubmed: 33513851
Atherosclerosis. 2013 Jun;228(2):426-31
pubmed: 23623262
Atherosclerosis. 2021 Dec;338:1-6
pubmed: 34741929
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Circulation. 2017 Mar 7;135(10):e146-e603
pubmed: 28122885
J Am Coll Cardiol. 2016 Jun 14;67(23):2719-2728
pubmed: 27046162